440 related articles for article (PubMed ID: 35178887)
1. Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
Papathanasiou M; Jakstaite AM; Oubari S; Siebermair J; Wakili R; Hoffmann J; Carpinteiro A; Hagenacker T; Thimm A; Rischpler C; Kessler L; Rassaf T; Luedike P
ESC Heart Fail; 2022 Jun; 9(3):1740-1748. PubMed ID: 35178887
[TBL] [Abstract][Full Text] [Related]
2. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
[No Abstract] [Full Text] [Related]
3. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis.
Donnellan E; Wazni O; Kanj M; Elshazly MB; Hussein A; Baranowski B; Hanna M; Patel D; Trulock K; Martyn M; Menon V; Saliba W; Jaber WA
Europace; 2020 Feb; 22(2):259-264. PubMed ID: 32031230
[TBL] [Abstract][Full Text] [Related]
4. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies.
Donnellan E; Wazni OM; Hanna M; Elshazly MB; Puri R; Saliba W; Kanj M; Vakamudi S; Patel DR; Baranowski B; Cantillon D; Dresing T; Jaber WA
JACC Clin Electrophysiol; 2020 Sep; 6(9):1118-1127. PubMed ID: 32972546
[TBL] [Abstract][Full Text] [Related]
5. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.
Longhi S; Quarta CC; Milandri A; Lorenzini M; Gagliardi C; Manuzzi L; Bacchi-Reggiani ML; Leone O; Ferlini A; Russo A; Gallelli I; Rapezzi C
Amyloid; 2015; 22(3):147-55. PubMed ID: 25997105
[TBL] [Abstract][Full Text] [Related]
6. Atrial function and geometry differences in transthyretin versus immunoglobulin light chain amyloidosis: a cardiac magnetic resonance study.
Palmer C; Truong VT; Slivnick JA; Wolking S; Coleman P; Mazur W; Zareba KM
Sci Rep; 2022 Jan; 12(1):140. PubMed ID: 34996915
[TBL] [Abstract][Full Text] [Related]
7. Association Between Atrial Uptake on Cardiac Scintigraphy With Technetium-99m-Pyrophosphate Labeled Bone-Seeking Tracers and Atrial Fibrillation.
Hussain M; Krywanczyk A; Donnellan E; Martyn T; Hassan OA; Alkharabsheh S; Watson C; Tang WH; Kwon D; Cremer P; Cheng F; Kanj M; Griffin B; Tan C; Rodriguez ER; Hanna M; Jaber W; Collier P
Circ Cardiovasc Imaging; 2022 May; 15(5):e013829. PubMed ID: 35580157
[TBL] [Abstract][Full Text] [Related]
8. Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.
Itzhaki Ben Zadok O; Vaturi M; Vaxman I; Iakobishvili Z; Rhurman-Shahar N; Kornowski R; Hamdan A
PLoS One; 2021; 16(8):e0255487. PubMed ID: 34370783
[TBL] [Abstract][Full Text] [Related]
9. Routine ambulatory heart rhythm monitoring for detection of atrial arrhythmias in transthyretin cardiac amyloidosis.
Dale Z; Chandrashekar P; Al-Rashdan L; Gill S; Elman M; Fischer KL; Nazer B; Masri A
Int J Cardiol; 2022 Jul; 358():65-71. PubMed ID: 35439584
[TBL] [Abstract][Full Text] [Related]
10. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.
Castaño A; Narotsky DL; Hamid N; Khalique OK; Morgenstern R; DeLuca A; Rubin J; Chiuzan C; Nazif T; Vahl T; George I; Kodali S; Leon MB; Hahn R; Bokhari S; Maurer MS
Eur Heart J; 2017 Oct; 38(38):2879-2887. PubMed ID: 29019612
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
12. When and how do patients with cardiac amyloidosis die?
Escher F; Senoner M; Doerler J; Zaruba MM; Messner M; Mussner-Seeber C; Ebert M; Ensinger C; Mair A; Kroiss A; Ulmer H; Schneiderbauer-Porod S; Ebner C; Poelzl G
Clin Res Cardiol; 2020 Jan; 109(1):78-88. PubMed ID: 31134330
[TBL] [Abstract][Full Text] [Related]
13. Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study.
Amat-Santos IJ; Delgado-Arana JR; Cruz-González I; Gutiérrez H; García-Bolao I; Millán X; Tirado-Conte G; Ruiz-Nodar JM; Mohandes M; Palazuelos J; Torres Saura F; Del Valle R; Valero Picher E; Núñez García JC; Gómez I; Albarrán Rincón R; Arzamendi D; Nombela-Franco L; Korniiko L; Barrero A; Santos-Martínez S; Serrador A; San Román JA
Rev Esp Cardiol (Engl Ed); 2023 Jul; 76(7):503-510. PubMed ID: 35934294
[TBL] [Abstract][Full Text] [Related]
14. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value.
Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C
JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225
[TBL] [Abstract][Full Text] [Related]
15. Atrial electrofunctional predictors of incident atrial fibrillation in cardiac amyloidosis.
Sinigiani G; De Michieli L; Porcari A; Zocchi C; Sorella A; Mazzoni C; Bisaccia G; De Luca A; Di Bella G; Gregori D; Perfetto F; Merlo M; Sinagra G; Iliceto S; Perazzolo Marra M; Corrado D; Ricci F; Cappelli F; Cipriani A
Heart Rhythm; 2024 Feb; ():. PubMed ID: 38309449
[TBL] [Abstract][Full Text] [Related]
16. Cardiac amyloidosis: a significant blind spot of the H2FPEF score.
Duca F; Rettl R; Binder C; Dusik F; Schrutka L; Dalos D; Öztürk B; Capelle CD; Qin H; Dachs TM; Camuz Ligios L; Agis H; Kain R; Hengstenberg C; Badr-Eslam R; Kastner J; Bonderman D
Panminerva Med; 2023 Dec; 65(4):491-498. PubMed ID: 36789997
[TBL] [Abstract][Full Text] [Related]
17. Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients.
Versteylen MO; Brons M; Teske AJ; Oerlemans MIFJ
Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892668
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
Donnellan E; Wazni OM; Saliba WI; Hanna M; Kanj M; Patel DR; Wilner B; Kochar A; Jaber WA
Am J Cardiol; 2020 Aug; 128():140-146. PubMed ID: 32650908
[TBL] [Abstract][Full Text] [Related]
19. Significant functional tricuspid regurgitation portends poor outcomes in patients with atrial fibrillation and preserved left ventricular ejection fraction.
Prapan N; Ratanasit N; Karaketklang K
BMC Cardiovasc Disord; 2020 Oct; 20(1):433. PubMed ID: 33023481
[TBL] [Abstract][Full Text] [Related]
20. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.
Porcari A; Rossi M; Cappelli F; Canepa M; Musumeci B; Cipriani A; Tini G; Barbati G; Varrà GG; Morelli C; Fumagalli C; Zampieri M; Argirò A; Vianello PF; Sessarego E; Russo D; Sinigiani G; De Michieli L; Di Bella G; Autore C; Perfetto F; Rapezzi C; Sinagra G; Merlo M
Eur J Heart Fail; 2022 Jul; 24(7):1227-1236. PubMed ID: 35509181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
